Patents by Inventor James Francis Callahan

James Francis Callahan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200062781
    Abstract: The present invention relates to bisaryl heterocycle compounds, methods of making them, pharmaceutical compositions containing them and their use as NRF2 activators.
    Type: Application
    Filed: December 11, 2017
    Publication date: February 27, 2020
    Inventors: James Francis CALLAHAN, Roderick S. DAVIS, Nicole Cathleen GOODWIN, Jeffrey K. KERNS
  • Patent number: 10485806
    Abstract: The present invention relates to aryl analogs, pharmaceutical compositions containing them and their use as NRF2 regulators.
    Type: Grant
    Filed: April 4, 2019
    Date of Patent: November 26, 2019
    Assignees: GlaxoSmithKline Intellectual Property Development Limited, Astex Therapeutics Limited
    Inventors: Jeffrey K. Kerns, James Francis Callahan, Hongxing Yan, Thomas Daniel Heightman, Jeffrey Charles Boehm, Alison Jo-Anne Woolford
  • Publication number: 20190330238
    Abstract: The present invention relates to bisaryl amide analogs, pharmaceutical compositions containing them and their use as NRF2 activators.
    Type: Application
    Filed: December 11, 2017
    Publication date: October 31, 2019
    Inventors: James Francis CALLAHAN, Vincent J. COLANDREA, Anthony William James COOPER, Nicole Cathleen GOODWIN, Chelsea Ariane HUFF, Joel KARPIAK, Jeffrey K. KERNS, Hong NIE
  • Publication number: 20190224212
    Abstract: The present invention relates to aryl analogs, pharmaceutical compositions containing them and their use as NRF2 regulators.
    Type: Application
    Filed: April 4, 2019
    Publication date: July 25, 2019
    Inventors: Jeffrey K. Kerns, James Francis Callahan, Hongxing Yan, Thomas Daniel Heightman, Jeffrey Charles Boehm, Alison Jo-Anne Woolford
  • Patent number: 10272095
    Abstract: The present invention relates to aryl analogs, pharmaceutical compositions containing them and their use as NRF2 regulators.
    Type: Grant
    Filed: June 15, 2016
    Date of Patent: April 30, 2019
    Assignees: GlaxoSmithKline Intellectual Propert Development Limited, Astex Therapeutics, Limited
    Inventors: Jeffrey K. Kerns, James Francis Callahan, Hongxing Yan, Thomas Daniel Heightman, Jeffrey Charles Boehm, Alison Jo-Anne Woolford
  • Patent number: 9227914
    Abstract: Novel calcilytic compounds and methods of using them are provided.
    Type: Grant
    Filed: March 6, 2015
    Date of Patent: January 5, 2016
    Assignee: GlaxoSmithKline, LLC
    Inventors: Robert W. Marquis, Linda N. Casillas, Joshi M. Ramanjulu, James Francis Callahan
  • Publication number: 20150183723
    Abstract: Novel calcilytic compounds and methods of using them are provided.
    Type: Application
    Filed: March 6, 2015
    Publication date: July 2, 2015
    Inventors: Robert W. MARQUIS, Linda N. Casillas, Joshi M. Ramanjulu, James Francis Callahan
  • Patent number: 8980950
    Abstract: Novel calcilytic compounds and methods of using them are provided.
    Type: Grant
    Filed: November 1, 2013
    Date of Patent: March 17, 2015
    Assignee: GlaxoSmithKline, LLC
    Inventors: Robert W. Marquis, Linda N. Casillas, Joshi M. Ramanjulu, James Francis Callahan
  • Publication number: 20140057980
    Abstract: Novel calcilytic compounds and methods of using them are provided.
    Type: Application
    Filed: November 1, 2013
    Publication date: February 27, 2014
    Applicant: GlaxoSmithKline, LLC
    Inventors: Robert W. Marquis, Linda N. Casillas, Joshi M. Ramanjulu, James Francis Callahan
  • Patent number: 8586631
    Abstract: Novel calcilytic compounds and methods of using them are provided.
    Type: Grant
    Filed: February 11, 2013
    Date of Patent: November 19, 2013
    Assignee: GlaxoSmithKline, LLC
    Inventors: Robert W. Marquis, Linda N. Casillas, Joshi M. Ramanjulu, James Francis Callahan
  • Patent number: 8399517
    Abstract: Novel calcilytic compounds and methods of using them are provided.
    Type: Grant
    Filed: September 30, 2010
    Date of Patent: March 19, 2013
    Assignee: GlaxoSmithKline, LLC
    Inventors: Robert W. Marquis, Linda N. Casillas, Joshi M. Ramanjulu, James Francis Callahan
  • Patent number: 8084449
    Abstract: The present invention is directed to novel compounds of Formula (I) and pharmaceutically acceptable salts thereof, pharmaceutical compositions and their use as dual chromaphores having inhibitory activity against PDE4 and muscarinic acetylcholine receptors (mAChRs), and thus being useful for treating respiratory diseases.
    Type: Grant
    Filed: February 5, 2009
    Date of Patent: December 27, 2011
    Assignee: Glaxo Group Limited
    Inventors: James Francis Callahan, Guoliang Lin, Zehong Wan, Hongxing Yan
  • Patent number: 8071588
    Abstract: The present invention relates to novel compounds of Formula (I) and their use in the treatment of respiratory diseases, including anti-inflammatory and allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rhinitis (e.g. allergic rhinitis), atopic dermatitis or psoriasis.
    Type: Grant
    Filed: February 5, 2009
    Date of Patent: December 6, 2011
    Assignee: Glaxo Group Limited
    Inventors: James Francis Callahan, Guoliang Lin, Zehong Wan, Hongxing Yan
  • Patent number: 8067408
    Abstract: The present invention is directed to novel compounds of Formula (I), pharmaceutical compositions and their use in therapy, for example as inhibitors of phosphodiesterase type IV (PDE4) and as antagonists of muscarinic acetylcholine receptors (mAChRs), in the treatment of/and or prophylaxis of respiratory diseases, including antiinflammatory and/or allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rhinitis (e.g. allergic rhinitis), atopic dermatitis or psoriasis.
    Type: Grant
    Filed: February 5, 2009
    Date of Patent: November 29, 2011
    Assignee: Glaxo Group Limited
    Inventors: James Francis Callahan, Guoliang Lin, Zehong Wan, Hongxing Yan
  • Publication number: 20110054021
    Abstract: Novel calcilytic compounds and methods of using them are provided.
    Type: Application
    Filed: September 30, 2010
    Publication date: March 3, 2011
    Inventors: ROBERT W. MARQUIS, LINDA N. CASILLAS, JOSHI M. RAMANJULU, JAMES FRANCIS CALLAHAN
  • Patent number: 7829594
    Abstract: Novel calcilytic compounds and methods of using them are provided.
    Type: Grant
    Filed: February 26, 2009
    Date of Patent: November 9, 2010
    Assignee: GlaxoSmithKline, LLC
    Inventors: Robert W. Marquis, Linda N. Casillas, Joshi M. Ramanjulu, James Francis Callahan
  • Publication number: 20090239897
    Abstract: Novel substituted 1,5,7-trisubstituted-1,8-napthyridin-2(1H)-one compounds; 1,5,7 trisubstituted-1,6-napthyridine-2-(1H)-one compounds and 1,5,7-trisubstituted quinoline-2(1H)-one compounds, processes for the preparation thereof, the use thereof in treating CSBP/p38 kinase mediated diseases and pharmaceutical compositions for use in such therapy.
    Type: Application
    Filed: May 15, 2009
    Publication date: September 24, 2009
    Inventors: JEFFREY CHARLES BOEHM, JAMES FRANCIS CALLAHAN, RALPH F. HALL, XICHEN LIN, KATHERINE LOUISE WIDDOWSON
  • Publication number: 20090203677
    Abstract: The present invention relates to novel compounds of Formula (I) and their use in the treatment of respiratory diseases, including anti-inflammatory and allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rhinitis (e.g. allergic rhinitis), atopic dermatitis or psoriasis.
    Type: Application
    Filed: February 5, 2009
    Publication date: August 13, 2009
    Applicant: Glaxo Group Limited
    Inventors: James Francis Callahan, Guoliang Lin, Zehong Wan, Hongxing Yan
  • Publication number: 20090203657
    Abstract: The present invention is directed to novel compounds of Formula (I) and pharmaceutically acceptable salts thereof, pharmaceutical compositions and their use as dual chromaphores having inhibitory activity against PDE4 and muscarinic acetylcholine receptors (mAChRs), and thus being useful for treating respiratory diseases.
    Type: Application
    Filed: February 5, 2009
    Publication date: August 13, 2009
    Applicant: Glaxo Group Limited
    Inventors: James Francis Callahan, Guoliang Lin, Zehong Wan, Hongxing Yan
  • Publication number: 20090197871
    Abstract: The present invention is directed to novel compounds of Formula (I), pharmaceutical compositions and their use in therapy, for example as inhibitors of phosphodiesterase type IV (PDE4) and as antagonists of muscarinic acetylcholine receptors (mAChRs), in the treatment of/and or prophylaxis of respiratory diseases, including antiinflammatory and/or allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rhinitis (e.g. allergic rhinitis), atopic dermatitis or psoriasis.
    Type: Application
    Filed: February 5, 2009
    Publication date: August 6, 2009
    Applicant: Glaxo Group Limited
    Inventors: James Francis Callahan, Guoliang Lin, Zehong Wan, Hongxing Yan